PacBio Enters Material Definitive Agreement

Ticker: PACB · Form: 8-K · Filed: 2025-03-13T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, financial-obligation

Related Tickers: PACB

TL;DR

PacBio signed a big deal, could mean new money or obligations.

AI Summary

On March 7, 2025, Pacific Biosciences of California, Inc. (PacBio) entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant.

Why It Matters

This filing signals a significant new contract or financial commitment for PacBio, which could impact its future operations and financial standing.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new financial risks or opportunities that are not yet fully understood.

Key Players & Entities

Pacific Biosciences of California, Inc. (company) — Registrant
March 7, 2025 (date) — Date of earliest event reported

FAQ

What type of material definitive agreement did Pacific Biosciences of California, Inc. enter into?

The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on March 7, 2025.

What is the nature of the direct financial obligation or off-balance sheet arrangement?

The filing states that a direct financial obligation or an obligation under an off-balance sheet arrangement was created, but does not provide specific details.

What is the Commission File Number for Pacific Biosciences of California, Inc.?

The Commission File Number for Pacific Biosciences of California, Inc. is 001-34899.

Where is Pacific Biosciences of California, Inc. headquartered?

Pacific Biosciences of California, Inc. is headquartered at 1305 O'Brien Drive, Menlo Park, California 94025.

What is the IRS Employer Identification Number for the company?

The IRS Employer Identification Number for Pacific Biosciences of California, Inc. is 16-1590339.

From the Filing

0001299130-25-000053.txt : 20250313 0001299130-25-000053.hdr.sgml : 20250313 20250313160634 ACCESSION NUMBER: 0001299130-25-000053 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250307 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant FILED AS OF DATE: 20250313 DATE AS OF CHANGE: 20250313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 25735765 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 8-K 1 pacb-20250307.htm 8-K pacb-20250307 0001299130 false 0001299130 2025-03-07 2025-03-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 7, 2025 Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34899 16-1590339 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1305 O’Brien Drive Menlo Park , California 94025 (Address of principal executive offices) (Zip Code) ( 650 ) 521-8000 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o ITEM 1.01.    ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. On March 7, 2025, Pacific Biosciences of California, Inc. (the “Company”) entered into a Third Amendment to Lease (the “Lease Amendment”) with Menlo Park Portfolio II, LLC (“Lessor”) to amend the Lease by and between Lessor and the Company, dated July 22, 2015, as amended by the First Amendment to Lease, dated December 23, 2016, and as further amended by the Second Amendment to Lease, dated December 30, 2019 (collectively, the “Lease”), relating to the Com